Cargando…
Optimal induction of myeloma cell death requires dual blockade of phosphoinositide 3-kinase and mTOR signalling and is determined by translocation subtype
Novel inhibitors of PI3K, Akt and mTOR have been developed recently, some of which have entered clinical trials. Although such compounds inhibit cell proliferation, their effects on cell survival, an important determinant of clinical response, are less clear-cut. Using a broad panel of myeloma cell...
Autores principales: | Stengel, Chloe, Cheung, Ching Wai, Quinn, John, Yong, Kwee, Khwaja, Asim |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392205/ https://www.ncbi.nlm.nih.gov/pubmed/22415553 http://dx.doi.org/10.1038/leu.2012.69 |
Ejemplares similares
-
Inhibition of cell cycle progression by dual phosphatidylinositol-3-kinase and mTOR blockade in cyclin D2 positive multiple myeloma bearing IgH translocations
por: Glassford, J, et al.
Publicado: (2012) -
mTOR Pathway and mTOR Inhibitors in Head and Neck Cancer
por: Gao, Wei, et al.
Publicado: (2012) -
Decursin and Doxorubicin Are in Synergy for the Induction of Apoptosis via STAT3 and/or mTOR Pathways in Human Multiple Myeloma Cells
por: Jang, Jinsil, et al.
Publicado: (2013) -
Blockade of the mTOR signaling pathway with rapamycin ameliorates aristolochic acid nephropathy
por: Wu, Minmin, et al.
Publicado: (2020) -
Therapeutic mTOR blockade in systemic autoimmunity: Implications for antiviral immunity and extension of lifespan
por: Geier, Christian, et al.
Publicado: (2021)